Developer docs
API playgroundTry for free, no card

Search company profiles

Intrinsic Imaging

Full company profile

uuid000qzqg

Namestring
Intrinsic Imaging
Legal namestring
Intrinsic Imaging, LLC
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Intrinsic Imaging is a full-service medical imaging core laboratory that supports pharmaceutical, biotechnology, medical device, and AI clinical-trial sponsors across Phase I–IV drug trials and Class I, II, and III device trials. The company provides end-to-end imaging services including protocol and charter design, site qualification and technologist training, centralized image collection and quality control, blinded independent central reads (single, double, and triple-read paradigms), endpoint adjudication, quantitative image analysis, biostatistics and 21 CFR Part 11-compliant data delivery, and regulatory submission support for the FDA, EMA, and PMDA. Its distinguishing infrastructure is a reader panel of 1,000+ board-certified, fellowship-trained physicians with documented sub-specialization across oncology, cardiology, CNS, gastroenterology, musculoskeletal, and ophthalmology, plus what the company describes as the only five-ISO-certified (and three FDA BIMO-inspected, zero-483) quality management system among imaging core labs. It also operates a specialized AI/CAD/Viewer validation practice built around multi-case multi-reader observer performance studies, with 55 large MRMC AI/CAD trials and tens of thousands of case reviews reported.

The business operates on a project/contract-based professional-services model: engagements are custom-quoted per study via a 'Request a Proposal' motion, with pricing varying by therapeutic area, phase, modality, reader count, case volume, and regulatory scope. Acquisition is enterprise-driven direct sales to clinical-trial sponsors — no channel partners, resellers, or self-serve channels — supported by a website and a leadership team with deep CRO/clinical-research pedigrees (CEO Todd A. Joron previously ran a $165M PAREXEL Perceptive Informatics P&L; CMO Dr. Amit Mehta is a Harvard/MGH-trained interventional radiologist and Builders VC General Partner). After being sold to WCG Clinical in 2021 for approximately $80 million, the business was reacquired by its founders in 2026 and returned to independent operation from its headquarters in Bolton, Massachusetts.

Short descriptiontext

Intrinsic Imaging is a U.S.-based, full-service medical imaging core laboratory that delivers end-to-end imaging endpoints, blinded central reads, and AI/CAD validation services for pharmaceutical, biotechnology, medical device, and AI clinical-trial sponsors running Phase I–IV drug and Class I–III device trials globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging core lab, clinical trial imaging, AI/CAD observer studies, radiology central reads, medical device trials
Industry4 codes
PRIMARYHLAGAEAH
Imaging Core Labs & Clinical Endpoint Adjudication
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAJ
Imaging Interoperability & Standards Enablement (DICOM/HL7/FHIR/IHE)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Medical Imaging Core Lab Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Imaging Core Lab Services
TypeProfessional Services
Description

Intrinsic Imaging generates revenue by providing comprehensive medical imaging core lab services to pharmaceutical, biotechnology, medical device, and AI clinical trial sponsors. Services include imaging protocol development, centralized image collection and QC, blinded independent reads, endpoint adjudication, quantitative image analysis, and regulatory submission support. Revenue is likely project/contract-based, driven by the number and complexity of clinical trials supported. The company operates on a per-study or per-service contractual model typical of core labs serving pharma/biotech clients.

intrinsicimaging.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing for clinical trial imaging services
ModelOther
Notes

No public pricing tiers or rate cards are published. All engagements are custom-quoted based on study scope, therapeutic area, imaging modalities, reader counts, case volumes, and regulatory requirements.

intrinsicimaging.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Intrinsic Imaging is a full-service medical imaging core laboratory that provides comprehensive imaging services to support Phase I-IV clinical trials and Class I, II, and III medical device trials. Services include imaging protocol and charter design, site qualification and training, centralized image collection and quality control, blinded independent central reads (single, double, triple-read paradigms), endpoint adjudication, quantitative image analysis, biostatistics, and regulatory submission support for FDA, EMA, and PMDA. The company is also a world leader in conducting stand-alone and multi-case multi-reader (MRMC) observer performance studies to evaluate AI/CAD/Viewer software.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 55 large MRMC AI/CAD trials completed with experience managing 10,000–30,000 case reviews
+3 more records
Product overview1 text field

Intrinsic Imaging is a full-service medical imaging core lab providing comprehensive imaging services for Phase I-IV clinical trials and Class I-III medical device trials. The core offering includes AI/CAD studies as a specialized service for FDA device clearance, independent central reads by sub-specialty radiologists, and therapeutic area-specific imaging services across six major areas: Oncology, Cardiology, Central Nervous System, Gastroenterology, Musculoskeletal, and Ophthalmology. The company operates with a team of 1000+ board-certified, fellowship-trained physicians and supports clinical trials in 65+ countries.

Product and service2 records
1Medical Imaging Core Lab Services
CategoryClinical Research Services
Description

Full-service medical imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, and III medical device trials, including imaging protocol development, site qualification, independent central reads, and endpoint adjudication for pharmaceutical, biotechnology, medical device, and AI clinical trial sponsors.

2AI / CAD Studies
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeOthersAnnounced on2021-01-01
Description

Intrinsic Imaging was acquired by WCG Clinical in 2021 in a transaction valued at approximately $80 million. The acquisition integrated Intrinsic Imaging's expertise into WCG Clinical's Scientific and Regulatory Division. Following the acquisition, company leadership continued to operate the business within WCG Clinical. In 2026, company founders Todd Joron and Dr. Amit Mehta reacquired Intrinsic Imaging, returning it to independent ownership.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clario (formed from the merger of Bioclinica and ERT) is the largest dedicated imaging core lab and eCOA provider for clinical trials, offering blinded independent central reads, MRMC studies, and therapeutic-area imaging services that directly overlap Intrinsic Imaging's core offering.

2IXICO
TypeDirect peer
Description

IXICO provides imaging biomarker and central read services for neuroscience and oncology clinical trials, with deep expertise in MRMC-style study design and AI-assisted image analysis — directly comparable to Intrinsic's CNS and AI/CAD work.

TypeDirect peer
Description

Median Technologies runs an imaging core lab (iCRO) for oncology clinical trials, providing independent central reads, RECIST-based response assessment, and AI-driven image analysis — overlapping directly with Intrinsic's oncology imaging and AI/CAD capabilities.

TypeDirect peer
Description

Calyx (which acquired VirtualScopics) provides medical imaging core lab services and AI-enabled quantitative imaging for clinical trials, with similar therapeutic-area breadth and FDA submission support to Intrinsic Imaging.

TypeDirect peer
Description

Worldcare Clinical is a dedicated imaging core lab serving pharma, biotech, and medical device sponsors with central reads, MRMC studies, and regulatory submission support, comparable in scope and customer base to Intrinsic Imaging.

TypeBroad incumbent
Description

ICON plc is a top-5 global CRO that bundles imaging core lab and central read services into its full-service Phase I-IV offering, representing a broader incumbent alternative to using a stand-alone imaging core lab like Intrinsic.

TypeBroad incumbent
Description

Medpace is a mid-to-large CRO with an in-house imaging core lab capability supporting its full-service clinical trial business, competing with Intrinsic for both imaging endpoints and broader trial outsourcing decisions.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO and offers integrated imaging and central laboratory services as part of its full-service trial platform, giving it significant bundling power against stand-alone imaging core labs like Intrinsic.

TypeBroad incumbent
Description

Fortrea (spun out of Labcorp's drug development business) is a global CRO with central imaging and endpoint adjudication services that overlap Intrinsic's offering and compete for pharma/biotech sponsor budgets.

TypeEmerging player
Description

Philips BioTel Research provides imaging core lab and cardiac monitoring services for clinical trials, with growing AI-enabled cardiac imaging capabilities that intersect Intrinsic's cardiology and AI/CAD practice areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intrinsic Imaging

Medical Imaging Core Lab Servicesintrinsicimaging.com

Intrinsic Imaging is a U.S.-based, full-service medical imaging core laboratory that delivers end-to-end imaging endpoints, blinded central reads, and AI/CAD validation services for pharmaceutical, biotechnology, medical device, and AI clinical-trial sponsors running Phase I–IV drug and Class I–III device trials globally.

What Intrinsic Imaging does

Intrinsic Imaging is a full-service medical imaging core laboratory that supports pharmaceutical, biotechnology, medical device, and AI clinical-trial sponsors across Phase I–IV drug trials and Class I, II, and III device trials. The company provides end-to-end imaging services including protocol and charter design, site qualification and technologist training, centralized image collection and quality control, blinded independent central reads (single, double, and triple-read paradigms), endpoint adjudication, quantitative image analysis, biostatistics and 21 CFR Part 11-compliant data delivery, and regulatory submission support for the FDA, EMA, and PMDA. Its distinguishing infrastructure is a reader panel of 1,000+ board-certified, fellowship-trained physicians with documented sub-specialization across oncology, cardiology, CNS, gastroenterology, musculoskeletal, and ophthalmology, plus what the company describes as the only five-ISO-certified (and three FDA BIMO-inspected, zero-483) quality management system among imaging core labs. It also operates a specialized AI/CAD/Viewer validation practice built around multi-case multi-reader observer performance studies, with 55 large MRMC AI/CAD trials and tens of thousands of case reviews reported.

The business operates on a project/contract-based professional-services model: engagements are custom-quoted per study via a 'Request a Proposal' motion, with pricing varying by therapeutic area, phase, modality, reader count, case volume, and regulatory scope. Acquisition is enterprise-driven direct sales to clinical-trial sponsors — no channel partners, resellers, or self-serve channels — supported by a website and a leadership team with deep CRO/clinical-research pedigrees (CEO Todd A. Joron previously ran a $165M PAREXEL Perceptive Informatics P&L; CMO Dr. Amit Mehta is a Harvard/MGH-trained interventional radiologist and Builders VC General Partner). After being sold to WCG Clinical in 2021 for approximately $80 million, the business was reacquired by its founders in 2026 and returned to independent operation from its headquarters in Bolton, Massachusetts.

Intrinsic Imaging firmographics

Firmographics
Name
Intrinsic Imaging
Legal name
Intrinsic Imaging, LLC
Website
https://intrinsicimaging.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Intrinsic Imaging is a U.S.-based, full-service medical imaging core laboratory that delivers end-to-end imaging endpoints, blinded central reads, and AI/CAD validation services for pharmaceutical, biotechnology, medical device, and AI clinical-trial sponsors running Phase I–IV drug and Class I–III device trials globally.
Ownership category
akta.pro rank

Intrinsic Imaging industry classification

Industry
Product category
Medical Imaging Core Lab Services
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAEAH
Imaging Core Labs & Clinical Endpoint Adjudication
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAJ
Imaging Interoperability & Standards Enablement (DICOM/HL7/FHIR/IHE)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Medical imaging core lab
  • Clinical trial imaging
  • AI/CAD observer studies
  • Radiology central reads
  • Medical device trials

Where Intrinsic Imaging is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Intrinsic Imaging business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Medical Imaging Core Lab Services: Intrinsic Imaging generates revenue by providing comprehensive medical imaging core lab services to pharmaceutical, biotechnology, medical device, and AI clinical trial sponsors. Services include imaging protocol development, centralized image collection and QC, blinded independent reads, endpoint adjudication, quantitative image analysis, and regulatory submission support. Revenue is likely project/contract-based, driven by the number and complexity of clinical trials supported. The company operates on a per-study or per-service contractual model typical of core labs serving pharma/biotech clients.

Pricing tiers

ModelBillingPrice
Other—Custom project-based pricing for clinical trial imaging services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Intrinsic Imaging product offering

Product offering

Core offering

Intrinsic Imaging is a full-service medical imaging core laboratory that provides comprehensive imaging services to support Phase I-IV clinical trials and Class I, II, and III medical device trials. Services include imaging protocol and charter design, site qualification and training, centralized image collection and quality control, blinded independent central reads (single, double, triple-read paradigms), endpoint adjudication, quantitative image analysis, biostatistics, and regulatory submission support for FDA, EMA, and PMDA. The company is also a world leader in conducting stand-alone and multi-case multi-reader (MRMC) observer performance studies to evaluate AI/CAD/Viewer software.

Product overview

Intrinsic Imaging is a full-service medical imaging core lab providing comprehensive imaging services for Phase I-IV clinical trials and Class I-III medical device trials. The core offering includes AI/CAD studies as a specialized service for FDA device clearance, independent central reads by sub-specialty radiologists, and therapeutic area-specific imaging services across six major areas: Oncology, Cardiology, Central Nervous System, Gastroenterology, Musculoskeletal, and Ophthalmology. The company operates with a team of 1000+ board-certified, fellowship-trained physicians and supports clinical trials in 65+ countries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Medical Imaging Core Lab Services Full-service medical imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, and III medical device trials, including imaging protocol development, site qualification, independent central reads, and endpoint adjudication for pharmaceutical, biotechnology, medical device, and AI clinical trial sponsors.
  • AI / CAD Studies

Quantifiable outcome

  • 55 large MRMC AI/CAD trials completed with experience managing 10,000–30,000 case reviews
  • +3 more outcomes

Companies that use Intrinsic Imaging

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Intrinsic Imaging technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Intrinsic Imaging partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • WCG ClinicalmajorOthers · 1 January 2021Intrinsic Imaging was acquired by WCG Clinical in 2021 in a transaction valued at approximately $80 million. The acquisition integrated Intrinsic Imaging's expertise into WCG Clinical's Scientific and Regulatory Division. Following the acquisition, company leadership continued to operate the business within WCG Clinical. In 2026, company founders Todd Joron and Dr. Amit Mehta reacquired Intrinsic Imaging, returning it to independent ownership.

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Intrinsic Imaging competitors and assessment

Company assessment

Direct peers

  • Clario: Clario (formed from the merger of Bioclinica and ERT) is the largest dedicated imaging core lab and eCOA provider for clinical trials, offering blinded independent central reads, MRMC studies, and therapeutic-area imaging services that directly overlap Intrinsic Imaging's core offering.
  • IXICO: IXICO provides imaging biomarker and central read services for neuroscience and oncology clinical trials, with deep expertise in MRMC-style study design and AI-assisted image analysis — directly comparable to Intrinsic's CNS and AI/CAD work.
  • Median Technologies: Median Technologies runs an imaging core lab (iCRO) for oncology clinical trials, providing independent central reads, RECIST-based response assessment, and AI-driven image analysis — overlapping directly with Intrinsic's oncology imaging and AI/CAD capabilities.
  • Calyx: Calyx (which acquired VirtualScopics) provides medical imaging core lab services and AI-enabled quantitative imaging for clinical trials, with similar therapeutic-area breadth and FDA submission support to Intrinsic Imaging.
  • Worldcare Clinical: Worldcare Clinical is a dedicated imaging core lab serving pharma, biotech, and medical device sponsors with central reads, MRMC studies, and regulatory submission support, comparable in scope and customer base to Intrinsic Imaging.

Broad incumbents

  • ICON plc: ICON plc is a top-5 global CRO that bundles imaging core lab and central read services into its full-service Phase I-IV offering, representing a broader incumbent alternative to using a stand-alone imaging core lab like Intrinsic.
  • Medpace: Medpace is a mid-to-large CRO with an in-house imaging core lab capability supporting its full-service clinical trial business, competing with Intrinsic for both imaging endpoints and broader trial outsourcing decisions.
  • IQVIA: IQVIA is the world's largest CRO and offers integrated imaging and central laboratory services as part of its full-service trial platform, giving it significant bundling power against stand-alone imaging core labs like Intrinsic.
  • Fortrea: Fortrea (spun out of Labcorp's drug development business) is a global CRO with central imaging and endpoint adjudication services that overlap Intrinsic's offering and compete for pharma/biotech sponsor budgets.

Emerging players

  • Philips BioTel Research: Philips BioTel Research provides imaging core lab and cardiac monitoring services for clinical trials, with growing AI-enabled cardiac imaging capabilities that intersect Intrinsic's cardiology and AI/CAD practice areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Intrinsic Imaging social profiles

Digital presence

Intrinsic Imaging compliance and trust

Trust signal

Compliance6 records

Intrinsic Imaging financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intrinsic Imaging leadership team

Management profile

Number of profiles

Profiles4 records

Intrinsic Imaging funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intrinsic Imaging M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intrinsic Imaging

What does Intrinsic Imaging do?

Intrinsic Imaging is a full-service medical imaging core laboratory that provides comprehensive imaging services to support Phase I-IV clinical trials and Class I, II, and III medical device trials. Services include imaging protocol and charter design, site qualification and training, centralized image collection and quality control, blinded independent central reads (single, double, triple-read paradigms), endpoint adjudication, quantitative image analysis, biostatistics, and regulatory submission support for FDA, EMA, and PMDA. The company is also a world leader in conducting stand-alone and multi-case multi-reader (MRMC) observer performance studies to evaluate AI/CAD/Viewer software.

Is Intrinsic Imaging a public or private company?

Intrinsic Imaging is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Intrinsic Imaging founded?

Intrinsic Imaging was founded in 2010. It employs 11 to 50 people.

Where is Intrinsic Imaging based?

Intrinsic Imaging is headquartered in Boston, United States, in the North America region.

How does Intrinsic Imaging make money?

One revenue line is on record: medical Imaging Core Lab Services.

Who are Intrinsic Imaging's main competitors?

Direct peers on record are Clario, IXICO, Median Technologies, Calyx and Worldcare Clinical. Broad incumbents are ICON plc, Medpace, IQVIA and Fortrea. Philips BioTel Research is listed as an emerging player.

Does Intrinsic Imaging have an API?

No public API is recorded for Intrinsic Imaging.

What industry is Intrinsic Imaging in?

Intrinsic Imaging's product category is Medical Imaging Core Lab Services. Its primary akta.pro industry code is HLAGAEAH, Imaging Core Labs & Clinical Endpoint Adjudication, with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Worcester Business JournalBolton medical firm acquired by NJ clinical research companyWCG, a clinical research company based in Princeton, New Jersey, has acquired Bolton-based Intrinsic Imaging, which will operate as WCG Intrinsic Imaging while retaining its current leadership and headquarters. The acquisition aims to expand WCG's capabilities in medical imaging technologies for clinical trials, driven by increasing regulatory and industry demand for visual safety and efficacy demonstrations. Financial terms of the deal were not disclosed.BioSpaceWCG Acquires Intrinsic Imaging, Leading Full-Service Medical Imaging Core LabWCG acquired Intrinsic Imaging, a full-service medical imaging core lab, on July 13, 2021. Intrinsic Imaging holds five ISO certifications and employs over 500 physicians. The acquired company will operate as WCG Intrinsic Imaging from its Bolton, Massachusetts headquarters.PR NewswireWCG Acquires Intrinsic Imaging, Leading Full-Service Medical Imaging Core LabWCG acquired Intrinsic Imaging, a medical imaging core lab provider, on July 13, 2021. Intrinsic Imaging holds five ISO certifications and a BSI quality system, and will operate from its Bolton, Massachusetts headquarters. The acquisition expands WCG's imaging capabilities for clinical trials.WcgclinicalWCG Acquires Intrinsic Imaging, Leading Full-Service Medical Imaging Core LabWCG announced the acquisition of Intrinsic Imaging, a global provider of medical imaging core lab services for clinical trials. This strategic move integrates Intrinsic Imaging's specialized capabilities into WCG's portfolio to enhance data integrity and regulatory support for drug, device, and AI studies. Following the acquisition, Intrinsic Imaging will operate as WCG Intrinsic Imaging while retaining its leadership structure and headquarters in Bolton, Massachusetts.PrwebIntrinsic Imaging Awarded GIST Clinical Trial for the Treatment of Gastrointestinal Stromal TumorsIntrinsic Imaging, an FDA audited medical imaging core lab, announced a multi-year clinical trial for gastrointestinal stromal tumors (GIST). The trial will include study management, image quality control, and radiologist evaluation using RECIST v1.1 and Choi criteria. The company's oncology team has 12 radiologists with experience in various assessment criteria.PrwebIntrinsic Imaging Appoints Industry Veteran James Warpula Vice President, Quality Assurance and ComplianceIntrinsic Imaging appointed James Warpula as Vice President of Quality Assurance and Compliance. He will oversee quality for imaging core lab services across clinical and medical device trials, bringing over 25 years of experience. The company is FDA audited and ISO certified.PrwebIntrinsic Imaging’s Quality Management System Attains ISO 27001 Informational Security CertificationIntrinsic Imaging's quality management system received ISO 27001 certification from the British Standards Institute for informational security in clinical trials. The company also holds ISO 9001, ISO 13485, ISO 22301, and GAMP5 certifications, and its most recent FDA audit yielded zero 483 observations.